Net Health Acquires PointRight®
News provided by
Share this article
Share this article
PITTSBURGH, Jan. 12, 2021 /PRNewswire/ Net Health, a leading provider of cloud-based software for specialty medical providers across the continuum of care, today announced that it has acquired PointRight® Inc., a leading provider of analytics and data-driven tools for the post-acute market. The acquisition adds to Net Health s expanding investments in analytics capabilities, which include the recent acquisition of Tissue Analytics in April 2020 and the earlier acquisition of Focus on Therapeutic Outcomes (FOTO).
The acquisition of PointRight expands Net Health s position and scale in the growing post-acute market. Additionally, the acquisition will enable Net Health s broad roster of hospital clients to better manage their skilled nursing facility (SNF) networks and support outcomes measurement and performance improvement in Medicare Advantage and managed Medicaid programs.
Learn more about Acute Myeloid Leukemia and ONUREG (CNW Group/Bristol Myers Squibb Canada Co.)
AML is a heterogeneous clonal disorder characterized by immature myeloid cell proliferation and bone marrow failure, and is the most common form of acute leukemia in adults, accounting for approximately 80 per cent of adult cases.
2,3,4 An estimated 40-60 per cent of patients aged 60 years and older and 60-80 per cent of patients under 60 years old will obtain complete remission through induction chemotherapy (IC); however, 50 per cent will relapse within a year.
5,6 Once a relapse occurs, long-term survival averages at six months.
7 In 2015, an estimated 1,235 Canadians were diagnosed with AML and the overall incidence rate in Canada is 3.46/100,000 people.
China ranked 96th out of 100 countries in Covid data transparency index
News provided by
Share this article
-
Index from TotalAnalysis highlights China s data credibility issues – as the WHO investigation is frustrated by further delays
-
Lockdown of 18 million in Hebei province triggers questions over China s real level of infections and fatalities
-
China has recorded no Covid deaths since May 2020
LONDON, Jan. 12, 2021 /PRNewswire/ As the WHO s Investigation into China continues to be hampered by bureaucratic delays, the world s largest country has been ranked a troubling 96th out of 100 nations in the Covid Data Transparency Index (CDTI) published by independent research group
SOC Telemed Hires Top Executive Roles from Global Leaders in Healthcare and Tech
Stephanie Harris joins from AMTEK, Ron Egan from GE Healthcare, to round off SOC s expanding leadership team
News provided by
Share this article
Share this article
RESTON, Va., Jan. 12, 2021 /PRNewswire/ SOC Telemed, Inc. (Nasdaq: TLMD), one of the largest national providers of acute care telemedicine, announced two key additions to its leadership team with the addition of Stephanie Harris as Chief Human Resources Officer and Ron Egan as Chief Customer Officer.
In her role as CHRO, Harris will lead SOC Telemed s people strategy, talent acquisition and development, total rewards, and succession planning. Harris brings nearly 25 years of human resource experience supporting high-growth, private companies, and highly matrixed, $5 billion+ global organizations. Harris joins SOC Telemed from Telular AMETEK, a leader in IoT solutions for the commercial telematics market, where she served as Vice Pre
Natera to Present New Colorectal Cancer Data at the 2021 ASCO GI Symposium
Oral presentation showcases the largest early-stage CRC cohort to date, further validating the serial use of Signatera™ for early recurrence detection and MRD assessment
News provided by
Share this article
SAN CARLOS, Calif., Jan. 12, 2021 /PRNewswire/
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the American Society of Clinical Oncology s 2021 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 15-17, 2021.
Natera will have one oral and one poster presentation, each describing the clinical performance of Signatera in patients with colorectal cancer (CRC).